LISTED digital medication management company MedAdvisor has announced another partnership with a health group, with a new Epilepsy Action Australia pact aiming to improve health outcomes across the country.
The partnership will see MedAdvisor the national non-profit organisation, working together to affect change at a time when an estimated 250,000 Australians are living with the disorder.
Medication is the first line of treatment in the management of epilepsy and as such MedAdvisor is anticipated to play "a crucial role in increasing medication adherence through its innovative medication management platform," MedAdvisor ceo Robert Read said.
MedAdvisor brings more than 700,000 people across Australia using the platform and is connected with over 45% of Australian pharmacies, Read said.
"In Australia, medication adherence in epilepsy is typically quite low, with just 60% of medication doses taken as prescribed.
"When doses are missed, there is an increased risk of seizure activity.
"Those who are using MedAdvisor for the management of epilepsy, are 15-20% more adherent to their medications, resulting in better health outcomes," he said.
Epilepsy Action Australia ceo and md Carol Ireland said MedAdvisor would be of great assistance to those living with the condition.
"We are excited to be partnering with MedAdvisor to help our community improve their health outcomes through medication adherence.
"Medications are a significant factor in the treatment of epilepsy and we believe MedAdvisor can deliver benefits to people living with epilepsy in the management of their medication," she added.
The above article was sent to subscribers in Pharmacy Daily's issue from 05 May 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 05 May 17